All In Biotech

Free tool

FAERS Monitor: Harliku

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 209449 or its brand name (Harliku, Nitisinone). Reports on generic versions are filed under their own applications.

Reports

287

Serious

178

62% of reports

Hospitalization

67

Death reported

35

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • liver transplant33
  • off label use32
  • hepatocellular carcinoma22
  • amino acid level increased20
  • product dose omission issue16
  • treatment noncompliance16
  • death14
  • hepatic failure13
  • hepatic cirrhosis12
  • hospitalisation12
  • alpha 1 foetoprotein increased10
  • drug ineffective10
  • vitiligo9
  • pruritus8
  • rash8

Reports by year received

View as table
YearReports
20063
20101
20111
20129
20135
20151
20163
20173
20186
201918
202033
202144
202242
202339
202434
202531
202614

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,872 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
amino acid level increasedSignal202029.31321.437,506
alpha 1 foetoprotein increasedSignal101045.0565.99,280
liver transplantSignal33671.3486.221,232
vitiligoSignal9282.3148.22,241
hepatocellular carcinomaSignal22212.6142.24,414
hepatic cirrhosisSignal1246.926.9494
hepatic failureSignal1331.618.6356
treatment noncomplianceSignal1621.413.3292
hospitalisationSignal125.73.342
product dose omission issueSignal164.02.533
off label useSignal322.71.933
pruritus81.50.81
rash81.30.70
death141.20.70
drug ineffective100.60.33

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.